A Non-Interventional Study on Type 2 Diabetes Mellitus Patient's Characteristics and Management by General Practitioners and Endocrinologists in the Russian Population (THESEUS)
Phase of Trial: Phase IV
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms THESEUS
- Sponsors AstraZeneca
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 27 Dec 2018 Planned End Date changed from 16 Dec 2018 to 30 Jun 2019.
- 27 Dec 2018 Planned primary completion date changed from 16 Dec 2018 to 30 Jun 2019.